Abstract 1617P
Background
Pancreatic carcinoma (PC) is an aggressive malignancy and the 4th cause of all cancer deaths worldwide. More than 30% of patients (pts) with PC are unresectable because of the local extension with a median overall survival (OS) of less than 1 year. FFX is superior to gem in the treatment of metastatic PC, in terms of OS and progression-free survival (PFS) but standard of care remains gem for LAPC.
Methods
Pts with histologically proven LAPC not suitable for surgery, WHO PS ≤1, no cardiac ischemia were eligible. Randomization was stratified by center, tumour localization (pancreas head yes/no), WHO PS (0 vs 1) and age (≤60 vs > 60 years [yrs]). Pts received FFX (every 14 days for 12 cycles) or Gem 1000 mg/m2 on days 1, 8, and 15 for six 28-day cycles excepted for cycle 1 with an infusion at D22. Primary endpoint was PFS. Secondary endpoints were OS, rate of secondary curative-intent surgery, objective response rate, disease control rate, time to treatment failure, quality of life (QoL) and safety. QoL outcomes and updated survival results since ESMO 2022 are presented here in the intent-to-treat population.
Results
A total of 171 pts aged 35-84 yrs were included and followed for maximum 5 yrs. With a median follow-up of 47.8 mo, 159 PFS events were observed. Median PFS was 9.7 mo (95% CI: 7.0; 11.7) vs 7.7 mo (95% CI: 6.2; 9.2) in FFX and gem arm respectively, stratified HR=0,71 (95% CI: 0.5; 1.00), p=.04 and median OS was 15.7 mo (95% CI: 11.9; 20.3) vs 14.9 mo (95% CI:11.7; 18.3), stratified HR=1.03 (95% CI: 0.73; 1.46), p=0.71. QoL was evaluated on 141 pts (68 in gem arm and 73 pts in FFX arm). No significant difference was observed between the two arms except on the diarrhea scale: rate of patients without deterioration was 50.4% (95% CI: 37.6.; 63.2) and 37.8% (95% CI: 25.9.; 51.5) in FFX arm vs 89,3% (95% CI: 78.5.; 95) and 63,2% (95% CI: 48.3.; 76) in Gem arm, at 3 and 6 mo respectively, p=0.002.
Conclusions
PRODIGE 29/NEOPAN trial results show that FFX yields significantly longer PFS compared to Gem and was well tolerated. No significant difference in OS and QoL was observed between both groups. More analysis are ongoing on QoL, and will be presented during ESMO meeting.
Clinical trial identification
NCT02539537.
Editorial acknowledgement
Legal entity responsible for the study
UNICANCER.
Funding
Institut National du Cancer (INCA) National League Against Cancer (Ligue contre le cancer).
Disclosure
M.P. Ducreux: Financial Interests, Personal, Invited Speaker: Roche, Amgen, Pierre Fabre, Merck Kga, Pfizer, Bayer, Lilly, Servier; Financial Interests, Personal, Advisory Board: Roche, Basilea, Sotio, Pierre Fabre, Boehringer Ingelheim, Rafael, Servier, Zymeworks, Ipsen, Bayer, HalioDX, Lilly, GSK, Daiichi Sankyo; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Funding, Partial funding of a trial evaluating the role of bevacizumab in NET: Roche; Financial Interests, Institutional, Funding, Partial funding of a trial evaluating the role of steptozotocin in NET: Keocyt; Financial Interests, Institutional, Local PI: Rafael, Amgen; Financial Interests, Institutional, Funding: Bayer; Other, Other, My wife is head of the oncology business unit in the French Affiliate of Sandoz: Sandoz France. F. Di Fiore: Financial Interests, Personal, Advisory Board: Amgen, BMS; Financial Interests, Personal, Invited Speaker: Merck, Bayer, Sanofi, Ipsen, AstraZeneca, Servier, Roche. L. Evesque: Financial Interests, Personal, Advisory Board: Servier, Amgen, MSD, Merck. J. Bachet: Non-Financial Interests, Personal, Advisory Board: Acobiom, Bayer, Biomunex, GSK, Merck, MSD, Pierre Fabre, Servier. T. Lecomte: Financial Interests, Personal, Invited Speaker: IPSEN, Pierre Fabre AstraZeneca, BMS; Financial Interests, Personal, Advisory Board: Sanofi, Merck, Servier, Amgen, Deciphera, Advanced Accelerator Applications, Pierre Fabre. O. Bouche: Financial Interests, Personal, Advisory Board: Amgen, Merck, Apmonia Therapeutics, Deciphera; Financial Interests, Personal, Invited Speaker: Servier, Pierre Fabre, Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22